Understanding how certain proteins affect opioid sensitivity and tolerance
Regulation of Opioid Sensitivity and Tolerance by Ubiquitin Ligase Signaling
['FUNDING_R01'] · SEATTLE CHILDREN'S HOSPITAL · NIH-11089578
This study is looking at how certain signals in our cells affect how our bodies react to opioid medications, using tiny worms that have been modified to mimic human responses, to help find safer ways to manage pain and lower the risk of addiction.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SEATTLE CHILDREN'S HOSPITAL (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11089578 on ClinicalTrials.gov |
What this research studies
This research investigates the role of ubiquitin ligase signaling in regulating how the body responds to opioid medications. By using a special model organism, C. elegans, that has been genetically modified to express human opioid receptors, researchers can study the effects of opioids on behavior in a controlled environment. The study employs advanced techniques in genetics and biochemistry to uncover the mechanisms behind opioid sensitivity and tolerance, which are critical for improving pain management and reducing addiction risks. The findings could lead to the development of safer opioid treatments with fewer side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who require opioid medications for pain management and are concerned about the risks of addiction and tolerance.
Not a fit: Patients who do not use opioids or have no need for pain management may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer opioid medications that minimize the risk of addiction and tolerance for patients in need of pain relief.
How similar studies have performed: Previous research has shown success in using genetic models to study opioid responses, indicating that this approach has potential for meaningful discoveries.
Where this research is happening
SEATTLE, UNITED STATES
- SEATTLE CHILDREN'S HOSPITAL — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRILL, BROCK — SEATTLE CHILDREN'S HOSPITAL
- Study coordinator: GRILL, BROCK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: addictive disorder